Abstract:
A series of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones were designed, synthesized and evaluated as selective HIV-1 RT enzyme inhibitors. The results of the HIV-1 RT kit based assay and MT-4 cell tests showed that eight compounds effectively inhibited human immunodeficiency virus type-1 (HIV-1) replication at 20-320 nM concentrations with minimal cytotoxicity in MT-4 as well as in CEM cells.
